Video content above is prompted by the following:
- What does a successful CRM prevention or screening program look like in practice?
- Can early intervention in patients with HF or T2D prevent CKD or vice versa?
- How can early screening for CKD be improved and effectively implemented across different healthcare settings?
- What specific steps can healthcare providers take to incentivize early screening and intervention for CRM conditions?
- How can payers structure their reimbursement models to incentivize early detection and management of conditions like CKD, HF, and T2D?
This activity is supported by an educational grant from Boehringer Ingelheim.